Gene Therapy Is Here To Stay: Should Bigger Companies Build, Buy, Or Partner?

Gene therapy’s tremendous potential to transform the treatment of both rare and common diseases has been understood for decades. But few may appreciate how imminently that revolution is upon us. This summer, approvals on both sides of the Atlantic – for beta thalassemia and cerebral adrenoleukodystrophy in the United States and for severe hemophilia A […]

Scaling the slope of enlightenment: Gene therapy progress and the future of healthcare

The gene therapy industry is undergoing a regulatory resurgence. After three years with no new therapies reaching patients in the United States, two approvals in the last two months – of hematopoietic stem cell (HSC) gene therapies for beta thalassemia and cerebral adrenoleukodystrophy – have doubled the number of gene therapies available here. Across the […]